We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MEDNAX (MD) Q3 Earnings In Line With Estimates, Decline Y/Y
Read MoreHide Full Article
MEDNAX, Inc.’s (MD - Free Report) third-quarter 2019 adjusted earnings of 91 cents per share came in line with the Zacks Consensus Estimate. Meanwhile, the bottom line declined 3.2% % year over year due to high expenses.
Quarterly Details
The company generated revenues of $889 million, surpassing the Zacks Consensus Estimate by 1.8%. However, the top line dipped 0.9% from the year-ago period.
Same-unit revenues inched up 4.2% year over year, mainly driven by higher patient volume.
General and administrative expenses rose 6.9% to $102.4 million due to higher legal, information technology and revenue cycle costs.
Interest expense of the company escalated 37.2% to $29.9 million for the third quarter, primarily due to higher effective interest rate on borrowings between two periods.
In the quarter under review, Adjusted EBITDA totaled $133 million, up 2.3% year over year.
As of Sep 30, 2019, the company had cash and cash equivalents of about $28.9 million, down 36.5% from the level at 2018 end.
The company incurred total debt of $1.9 billion, down 1.8% from the level at 2018 end and total assets of $4.2 billion, down 27.7% from the level at 2018 end.
Cash flows from operating activities were $155.9 million, up 15.3% year over year.
Fourth-Quarter Outlook
For the fourth quarter of 2019, the company expects adjusted EPS in the band of 87-95 cents.
This guidance assumes that total same-unit revenue growth for the three months ended Dec 31, 2019 will be in a 1-3% range from the prior-year period. It also assumes that the effective tax rate for the fourth quarter is 26.5%.
Shares outstanding are predicted to be around 83.4 million.
Adjusted EBITDA from continuing operations is expected between $125 million and $135 million.
2019 Guidance
Based on its third-quarter results, the company now expects Adjusted EBITDA for the full year to be around $500 million.
Among other players from the medical sector, having already reported third-quarter earnings, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) , Anthem Inc. and Centene Corporation (CNC - Free Report) topped the respective Zacks Consensus Estimate.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MEDNAX (MD) Q3 Earnings In Line With Estimates, Decline Y/Y
MEDNAX, Inc.’s (MD - Free Report) third-quarter 2019 adjusted earnings of 91 cents per share came in line with the Zacks Consensus Estimate. Meanwhile, the bottom line declined 3.2% % year over year due to high expenses.
Quarterly Details
The company generated revenues of $889 million, surpassing the Zacks Consensus Estimate by 1.8%. However, the top line dipped 0.9% from the year-ago period.
Same-unit revenues inched up 4.2% year over year, mainly driven by higher patient volume.
General and administrative expenses rose 6.9% to $102.4 million due to higher legal, information technology and revenue cycle costs.
Interest expense of the company escalated 37.2% to $29.9 million for the third quarter, primarily due to higher effective interest rate on borrowings between two periods.
In the quarter under review, Adjusted EBITDA totaled $133 million, up 2.3% year over year.
Mednax, Inc Price, Consensus and EPS Surprise
Mednax, Inc price-consensus-eps-surprise-chart | Mednax, Inc Quote
Financial Update
As of Sep 30, 2019, the company had cash and cash equivalents of about $28.9 million, down 36.5% from the level at 2018 end.
The company incurred total debt of $1.9 billion, down 1.8% from the level at 2018 end and total assets of $4.2 billion, down 27.7% from the level at 2018 end.
Cash flows from operating activities were $155.9 million, up 15.3% year over year.
Fourth-Quarter Outlook
For the fourth quarter of 2019, the company expects adjusted EPS in the band of 87-95 cents.
This guidance assumes that total same-unit revenue growth for the three months ended Dec 31, 2019 will be in a 1-3% range from the prior-year period. It also assumes that the effective tax rate for the fourth quarter is 26.5%.
Shares outstanding are predicted to be around 83.4 million.
Adjusted EBITDA from continuing operations is expected between $125 million and $135 million.
2019 Guidance
Based on its third-quarter results, the company now expects Adjusted EBITDA for the full year to be around $500 million.
Zacks Rank
MEDNAX carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Players
Among other players from the medical sector, having already reported third-quarter earnings, the bottom-line results of UnitedHealth Group Incorporated (UNH - Free Report) , Anthem Inc. and Centene Corporation (CNC - Free Report) topped the respective Zacks Consensus Estimate.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>